These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 15473253)

  • 21. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug treatment of obesity].
    Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
    Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging concepts in the medical and surgical treatment of obesity.
    Aylwin S; Al-Zaman Y
    Front Horm Res; 2008; 36():229-259. PubMed ID: 18230906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy of obesity.
    Finer N
    Best Pract Res Clin Endocrinol Metab; 2002 Dec; 16(4):717-42. PubMed ID: 12468417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological intervention: the antiobesity approach.
    Rissanen A
    Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy for obesity.
    Li M; Cheung BM
    Br J Clin Pharmacol; 2009 Dec; 68(6):804-10. PubMed ID: 20002075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior.
    Anghelescu I; Klawe C; Szegedi A
    J Clin Psychopharmacol; 2002 Oct; 22(5):521-4. PubMed ID: 12352278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.
    Coutinho W
    Arq Bras Endocrinol Metabol; 2009 Mar; 53(2):262-70. PubMed ID: 19466219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
    Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
    Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modern medical management of obesity: the role of pharmaceutical intervention.
    Aronne LJ
    J Am Diet Assoc; 1998 Oct; 98(10 Suppl 2):S23-6. PubMed ID: 9787732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.
    Avenell A; Broom J; Brown TJ; Poobalan A; Aucott L; Stearns SC; Smith WC; Jung RT; Campbell MK; Grant AM
    Health Technol Assess; 2004 May; 8(21):iii-iv, 1-182. PubMed ID: 15147610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy for obesity.
    Ioannides-Demos LL; Proietto J; McNeil JJ
    Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-obesity drugs: sibutramine and orlistat].
    Sempere I Verdú E; Palop Larrea V; Hidalgo Mora JJ; Martínez-Mir I
    Med Clin (Barc); 2002 Mar; 118(11):437; author reply 437-8. PubMed ID: 11943108
    [No Abstract]   [Full Text] [Related]  

  • 39. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The endocannabinoid system as a target for obesity treatment.
    Aronne LJ; Pagotto U; Foster GD; Davis SN
    Clin Cornerstone; 2008; 9(1):52-64; discussion 65-6. PubMed ID: 19046740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.